scholarly journals Effect of oral administration of DHA on the remodeling of calcium handling proteins in congestive heart failure in male rats

2015 ◽  
Vol 29 (S1) ◽  
Author(s):  
Tomoko Yamanushi ◽  
Hideaki Kabuto ◽  
Kaoru Akiyama ◽  
Tadahiro Tsushima ◽  
Yoshihisa Misawa
2014 ◽  
Vol 144 (4) ◽  
pp. 467-474 ◽  
Author(s):  
Tomoko T. Yamanushi ◽  
Hideaki Kabuto ◽  
Eiichiro Hirakawa ◽  
Najma Janjua ◽  
Fusako Takayama ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-7
Author(s):  
Yao Wu ◽  
Feifei Si ◽  
Xiaojuan Ji ◽  
Kunfeng Jiang ◽  
Sijie Song ◽  
...  

Background. This study was undertaken to determine relative contributions of phosphorylation and oxidation to the increased activity of calcium/calmodulin-stimulated protein kinase II (CaMKII) in juveniles with cardiac myocyte dysfunction due to increased pressure overload. Methods. Juvenile rats underwent abdominal aortic constriction to induce heart failure. Four weeks after surgery, rats were then randomly divided into two groups: one group given valsartan (HF + Val) and the other group given placebo (HF + PBO). Simultaneously, the sham-operated rats were randomly given valsartan (Sham + Val) or placebo (Sham + PBO). After 4 weeks of treatment, Western blot analysis was employed to quantify CaMKII and relative calcium handling proteins (RyR2 and PLN) in all groups. Results. The deteriorated cardiac function was reversed by valsartan treatment. In ventricular muscle cells of group HF + PBO, Thr287 phosphorylation of CaMKII and S2808 phosphorylation of RyR2 and PLN were increased and S16 phosphorylation of PLN was decreased compared to the other groups, while Met281 oxidation was not significantly elevated. In addition, these changes in the expression of calcium handling proteins were ameliorated by valsartan administration. Conclusions. The phosphorylation of Thr286 is associated with the early activation of CaMKII rather than the oxidation of Met281.


Circulation ◽  
1985 ◽  
Vol 71 (5) ◽  
pp. 963-971 ◽  
Author(s):  
B Massie ◽  
M Bourassa ◽  
R DiBianco ◽  
M Hess ◽  
M Konstam ◽  
...  

2008 ◽  
Vol 1 (2) ◽  
pp. 93-102 ◽  
Author(s):  
Yung-Hsin Yeh ◽  
Reza Wakili ◽  
Xiao-Yan Qi ◽  
Denis Chartier ◽  
Peter Boknik ◽  
...  

1994 ◽  
Vol 267 (6) ◽  
pp. H2245-H2254 ◽  
Author(s):  
M. Naitoh ◽  
H. Suzuki ◽  
M. Murakami ◽  
A. Matsumoto ◽  
K. Arakawa ◽  
...  

Rapid right ventricular pacing could induce congestive heart failure in conscious dogs with significant increase in plasma concentration of arginine vasopressin (AVP) (from 1.2 +/- 0.2 to 3.4 +/- 0.6 pg/ml). In this experimental model of heart failure, oral administration of the selective AVP V1 receptor antagonist OPC-21268 significantly increased cardiac output and improved renal function without significant changes in serum electrolytes and hormones. Oral administration of the selective AVP V2 receptor antagonist OPC-31260 induced marked water diuresis, which resulted in significant increases in serum sodium concentration, plasma renin activity, and plasma concentration of AVP, although it did not produce hemodynamic improvement. Combined administration of OPC-21268 and OPC-31260 showed supra-additive hemodynamic responses as well as additive renal and metabolic responses, i.e., it showed prolonged decrease in mean arterial pressure and profound increase in cardiac output. These results suggest that AVP plays a significant role in elevation of vascular tone through V1 receptors and plays a major role in retaining free water through V2 receptors in this model of heart failure. Furthermore, combined administration of V1 and V2 receptor antagonists could induce not only metabolic and hormonal responses but also more beneficial hemodynamic responses than those observed following treatment with V1 receptor antagonist alone.


2012 ◽  
Vol 18 (9) ◽  
pp. 724-733 ◽  
Author(s):  
Holly R. Middlekauff ◽  
Chris Vigna ◽  
M. Anthony Verity ◽  
Gregg C. Fonarow ◽  
Tamara B. Horwich ◽  
...  

Hearts ◽  
2020 ◽  
Vol 1 (2) ◽  
pp. 86-98
Author(s):  
Stephen Schaffer ◽  
Takashi Ito ◽  
Junichi Azuma ◽  
Chian Jong ◽  
Jay Kramer

Taurine is a ubiquitous β-amino acid that plays an essential role in ensuring normal mitochondrial and myocardial function. In the mitochondria, taurine reacts with a tRNA forming a 5-taurinomethyluridine conjugate that primarily regulates the biosynthesis of the mitochondria encoded protein, ND6, which serves as a subunit of complex I of the respiratory chain. Impaired formation of the taurine conjugate reduces activity of complex I and plays a central role in the pathophysiology of the mitochondrial disease MELAS (myopathy, encephalopathy, lactic acidosis and stroke-like episodes). The restoration of mitochondrial levels of the taurine conjugate enhances electron flux through the respiratory chain, thereby preventing at least some of the symptoms of MELAS. Taurine therapy also diminishes the severity of congestive heart failure, an observation that led to its approval for the treatment of congestive heart failure in Japan. The review article discusses the role of defective calcium handling, reduced ATP generation, enhanced oxidative stress and apoptosis in the development of taurine-deficient cardiomyopathy. Some patients suffering from congestive heart failure are taurine-deficient, an observation supporting the hypothesis that low taurine levels contribute to the severity of heart failure. Thus, mishandling of taurine leads to mitochondrial dysfunction, which is involved in the development of both MELAS and congestive heart failure.


Sign in / Sign up

Export Citation Format

Share Document